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Abstract
Background: A prospective study aiming at assessing the effect of adding a third dose sulphadoxine-
pyrimethamine (SP) to the standard two-dose intermittent preventive treatment for pregnant women was carried
out in Hounde, Burkina Faso, between March 2006 and July 2008. Pregnant women were identified as earlier as
possible during pregnancy through a network of home visitors, referred to the health facilities for inclusion and
followed up until delivery.
Methods: Study participants were enrolled at antenatal care (ANC) visits and randomized to receive either two or
three doses of SP at the appropriate time. Women were visited daily and a blood slide was collected when there
was fever (body temperature > 37.5°C) or history of fever. Women were encouraged to attend ANC and deliver in
the health centre, where the new-born was examined and weighed. The timing and frequency of malaria infection
was analysed in relation to the risk of low birth weight, maternal anaemia and perinatal mortality.
Results: Data on birth weight and haemoglobin were available for 1,034 women. The incidence of malaria
infections was significantly lower in women having received three instead of two doses of SP. Occurrence of first
malaria infection during the first or second trimester was associated with a higher risk of low birth weight:
incidence rate ratios of 3.56 (p < 0.001) and 1.72 (p = 0.034), respectively. After adjusting for possible confounding
factors, the risk remained significantly higher for the infection in the first trimester of pregnancy (adjusted
incidence rate ratio = 2.07, p = 0.002). The risk of maternal anaemia and perinatal mortality was not associated
with the timing of first malaria infection.
Conclusion: Malaria infection during first trimester of pregnancy is associated to a higher risk of low birth weight.
Women should be encouraged to use long-lasting insecticidal nets before and throughout their pregnancy.
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Background
Each year, about 30 million pregnant women are at risk
for malaria [1], with consequences of public health con-
cern [2]. Indeed, malaria infection may result in mater-
nal anaemia [3], pre-term delivery and low birth weight
(LBW) [2,4] and is therefore an important determinant
of perinatal mortality [5-7]. To prevent and manage
malaria in pregnancy, the Word Health Organization
(WHO) recommends effective case management, use of
insecticide-treated bed nets and intermittent preventive
treatment (IPTp) with sulphadoxine-pyrimethamine (SP)
[8]. Following the latest WHO guidelines, IPTp should
be administered at least twice, during the second and
third trimester. In Burkina Faso in 2005, the Ministry of
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phylaxis, whose efficacy had declined because of wide-
spread resistance [9], with IPTp/SP [10]. Several studies
have demonstrated the excellent safety and efficacy of
IPTp [11-15]. Most studies used maternal anaemia and
LBW as impact indicators. IPTp prevents the adverse
effects of malaria during pregnancy by clearing any
active infection and providing post-treatment prophy-
laxis. The length of protection may become shorter and
infection may occur progressively earlier as SP resistance
increases [16]. As SP is given at least twice during preg-
nancy, its prophylactic efficacy may vary according to
both the timing of malaria infection and SP administra-
tion. Unfortunately, because of fears of possible toxicity,
SP cannot be given during the first trimester of preg-
nancy. However, there is also little information on the
consequence of malaria infection during the first trime-
ster as most information available refers to infections
occurring in the second and third trimester [17-20]. A
randomized trial comparing two doses versus three
doses of IPTp/SP was carried out in rural Burkina Faso.
Participants were recruited as early as possible during
pregnancy and followed-up prospectively until delivery,
allowing an estimation of the effect of malaria infection
at different gestational ages on the risk of maternal
anaemia, LBW and perinatal mortality. Results are
reported below.
Methods
Study settings
Two peripheral health centres (Koho and Karaba) in the
Houndé health district, south-west Burkina-Faso, were
selected for the study. In this area, malaria is markedly
seasonal with high transmission during the rainy season
(June to December) [21]. The district hospital and the
28 peripheral health facilities cover a population of
approximately 247,500 people. In 2007, the number of
pregnant women at risk of malaria was estimated at
12,500, while malaria was the main disease in the health
district, accounting for about 38% of all consultations
and 52% of hospitalizations.
Study design
This was part of a larger study investigating both the effect
of multiple micronutrients supplementation (MMS) versus
fortified food supplementation (FFS) and that of IPTp/SP,
two versus three doses on the health of pregnant women
and that of their offspring. Participants were randomized
in permuted blocks of four to receive either two doses of
SP as recommended by the National Malaria Control Pro-
gramme (NMCP) or three doses. Randomization numbers
were generated by a computer program, sealed in opaque
envelopes and opened only when an eligible subject was
identified. These numbers were then transmitted to the
study pharmacist who packaged the drugs in individual
plastic zip bags. Each bag was labelled with the partici-
pant’s name, identification, residence, and randomization
group. The field pharmacist prepared for each woman an
individual schedule for SP administration according to the
gestational age at randomization and transmitted it to the
trained home visitors who administered both SP and
either MMS or FSS. Results of the nutrition intervention
have been reported elsewhere [22]. The effect of IPTp
with three doses of SP versus two doses of SP on LBW
and pregnancy outcomes have also been reported in a pre-
vious publication [23].
Study participants
Pregnant women were identified through a community-
based network of home visitors, as described elsewhere
[22]. All women of child-bearing age in the study area
were identified and paid monthly visits during which
they were screened for pregnancy. Women suspected to
be pregnant were referred to the health facilities for a
pregnancy test. The study protocol and procedures were
then explained to the potential participants in the local
language and those agreeing to participate were asked to
provide a written inform consent. Women with known
hypersensibility to SP or not planning to stay in the study
area for the next two years were excluded.
Recruitment and follow-up
Study participants were recruited at ANC clinics, where
the health staff recorded demographic data, medical and
pregnancy history. In addition, a clinical examination was
performed and vital signs, weight, height and arm circum-
ference were measured. All measures were repeated at
each ANC visit. Gestational age was assessed as early as
possible by the study obstetrician using trans-abdominal
ultrasound fetal biometry. Women included in the study
were visited at home daily by the home visitors who
recorded the body temperature and registered any com-
plaint. In case of fever (body temperature ≥ 37.5°C) or his-
tory of fever since the last visit, a blood sample for thick
and thin film was collected and sent to the health district
laboratory. All women with a confirmed malaria infection
were treated with a full course of quinine (24 mg/kg/day
for seven days), regardless of their gestational age. Preg-
nant women were encouraged to attend their scheduled
ANC visits and to deliver at the health facilities where the
new-borns was examined, weighed and measured twice by
two different members of the health staff.
Laboratory methods
Thick and thin blood smears were collected in duplicate
and stained with Giemsa 10% (pH 7.2) for 10 minutes.
Parasite densities were determined on the thick smears
by counting asexual parasites per 200 white blood cells
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blood smear was considered negative after reading 100
high-power fields. Ten percent of the slides were ran-
domly selected and sent to the Laboratory of Parasitol-
ogy/Centre Muraz for quality control. Haemoglobin
(Hb) was measured by using a portable spectrophot-
ometer (HemoCue, Angelholm, Sweden).
Ethics
The study protocol was approved by the ethical commit-
tees of the Centre Muraz, Bobo-Dioulasso, Burkina Faso,
and the University of Antwerp, Belgium. The trial was
registered in the ClinicalTrial.gov registry (identifier:
NCT00909974). The study purpose and procedures where
explained to the potential participants by the study clini-
cian in the local languages. Women who fulfilled the
inclusion criteria and agreed to participate in the study
were asked to provide a written inform consent.
Definitions and statistical analysis
A new-born was classified as LBW if the birth weight was
< 2,500 g. Women with haemoglobin levels < 11 g/dl
were classified as anaemic, those with haemoglobin levels
< 8 g/dl were classified as having moderate-to-severe
anaemia. Neonatal death was defined as one occurring
between delivery and 28 days of life. Malaria infection
was defined as a slide positive for Plasmodium falci-
parum, any density. Incidence rates were computed con-
sidering the follow-up duration time (in months) of each
woman. Women with a malaria infection after previous
treatment with quinine were considered as re-infected.
Time to re-infection was defined as the period between
the first infection parasite clearance and the second infec-
tion. As the parasite clearance was not monitored, we
calculated an adjusted time to re-infection considering
that all parasites were cleared after three days as indi-
cated in a previous publication [24].
Data were double entered in a Microsoft Access
® data-
base by two data clerks. Validation and analysis were per-
formed using Stata 10 IC
® software. Only singleton
pregnancies were included in the analysis. The Chi2 or
Fisher exact test were used to compare proportions for
categorical variables while a t-test for normally distribu-
ted or Mann-Whitney test for non-normally distributed
was used for continuous variables at baseline. A multi-
variate analysis using a Poisson regression model with
robust standard error estimates to evaluate the relation-
ship between explanatory variables and outcomes was
also performed. Crude and adjusted incidence rate ratios
(IRR) with 95% CI were computed. A p-value ≤ 0.05 was
considered as statistically significant.
The timing of malaria infection was defined according
to the first infection detect e da tt h ef i r s t ,s e c o n do r
third trimester of pregnancy. The frequency of malaria
infection was categorized according to the number of
positive slides detected during the whole pregnancy, i.e.
0, 1, or ≥ 2. Explanatory variables and possible confoun-
ders included the number of SP doses received (two or
three), the nutritional supplementation (FFS or MMS),
gravidity, body mass index at enrolment (underweight:
body mass index < 18.5 kg/m
2;o rn o r m a lw e i g h ,B M I≥
18.5 kg/m
2), and malaria transmission season at delivery
(low transmission season between December and May
and high transmission season between June and
November).
Results
Study population
From March 2006 to July 2008, 1,296 women were ran-
domized into the study. Table 1 shows the baseline
characteristics of study population according to the tim-
ing of first infection. Characteristics of study participants
according to randomization groups were published else-
where [23]. A total of 1,053 women attended at least
three ANC visits while 121 and 100 attended two and
one ANC visit, respectively. Analysis was performed on
1,034 women with complete records on birth weight
and haemoglobin. The mean maternal age was 24.4
years and the mean gestational age at enrolment was
15.9 weeks. There was no difference in terms of base-
lines characteristics between women included in the
analysis and those excluded for missing data.
Incidence rates of malaria detected infections
The overall incidence rate (IR) of malaria infection
(expressed per 1,000 women-months) was 39.2, and was
significantly higher in primi- (88.6, 95%CI: 72.6-108.1)
than in secundi- (50.6, 95%CI: 39.1-65.5) and multi-
gravidae (18.8, 95%CI: 14.7-24.1) (Table 2). The IR of
malaria infection was significantly lower (p = 0.014) in
women having received three (23.8%, 95%CI: 15.5-36.4)
than two SP doses (46.6%, 95%CI: 38.3-55.4). No differ-
ence between the MMS group (40.4, 95%CI: 33.5-48.6)
and the FFS group (38.0%, 95%CI: 31.5-45.9) was found
(p = 0.42).
Rates of re-infection and length of time-to-reinfection
The overall incidence of re-infections after quinine
treatment was 11.4% (95%CI: 8.9-14.6) and was signifi-
cantly higher (p < 0.001) in primi- (34.7, 95%CI: 25.3-
47.7) than in secundi- (11.3, 95%CI: 6.6-19.5) and multi-
gravidae (3.6%, 95%CI: 2.1-6.4). Re-infection tended to
be lower in women having received three (6.8%, 95%CI:
3.1-15.1) than two (14.3%, 95%CI: 10.2-19.9) SP doses
(p = 0.06). No difference between MMS and FFS group
was found (data not shown).
Overall, the adjusted mean time to re-infection was 59.3
days (95%CI: 45.8-72.7) with no difference by gravidity, i.e.
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(95%CI: 07.9-73.4), and multi-gravidae 51.2 days (95%CI:
3.2-99.1). Mean time to reinfection was not analysed by
number of SP doses as only four women in the three-dose
group were re-infected.
Effect of timing and frequency of malaria infection on
low birth weight, maternal anaemia and perinatal
mortality
When considering the timing of the first infection, no
significant difference could be found for maternal ane-
mia and perinatal mortality, while women infected both
in the first (IRR = 3.56, p <0 . 0 0 1 )a n dt h es e c o n dt r i -
mester (IRR = 1.72, p = 0.034) had a significantly higher
risk of delivering a LBW baby as compared to women
without any infection (Table 3). After adjusting for age,
parity, body mass index, number of SP doses received
and malaria season at delivery, such risk remained sig-
nificantly higher for women infected in the first trime-
ster of pregnancy (adjusted IRR = 2.07, p = 0.002)
(Table 3). Also, women infected in first trimester had a
significantly higher risk of delivering a LBW when com-
pared to women infected in the third trimester (Crude
IRR = 3.09, 95%CI: 1.66-5.73, p <0 . 0 1 ;a n da d j u s t e d
Table 1 Characteristic of study participants at inclusion by timing of first infection
Characteristics No infection
(n = 816)
Infection in first trimester
(n = 31)
Infection in second trimester
(n = 69)
Infection in third trimester
(n = 118)
Study location
Karaba village (n, %) 219 (26.84) 14 (45.16) 20(33.90) 40(33.94)
Koho village (n, %) 597 (73.16) 17 (54,84) 49(66.10) 78(66.06)
Education
none (n, %) 728 (89.21) 22 (70.97) 62(89.86) 105 (88.99)
primary (n, %) 69 (8.46) 8 (25.81) 7(10.14) 10 (8.47)
secondary and higher (n, %) 19(2.33) 1 (3.22) 0(0) 3(2.54)
Parity
primigravidae (n, %) 113 (13.85) 18 (58.06) 35 (50.72) 44 (37.29)
secundigravidae (n, %) 158 (19.36) 5 (16.13) 15 (21.74) 38 (32.20)
multigravidae (n, %) 545 (66.79) 8 (25.81) 19 (27.54) 36 (30.51)
Age
mean (years) (95% CI) 25.27(24.84-25.69) 20.88 (18.96-22.80) 21.27 (20.06-22.48) 21.50 (20.63-22.37)
Weight
mean (kg) (95% CI] 55.67 (55.17-56.15) 55.45 (53.20-57.71) 55.24 (53.70-56.79) 55.29 (54.08-56.50)
Height 162.815 163.39 162.58 161.78
mean (cm) (95% CI] (162.42-163.21) (161.72-165.08) (161.15-164.00) (160.71-162.85)
BMI at enrolment 20.98 20.77 20.88 21.1
mean (95% CI] (20.83-21.12) (19.97-21.56) (20.41-21.34) (20.74-21.45)
Table 2 Number of cases and incidence rates of malaria infections in the study population (per 1000 women-month)
Person-time* Malaria infections
new cases IR (per 1000)
(95% CI)
IRR (95% CI)
By Gravidity
Overall 5541 217 39.2 (34.3-44.7) -
Primigravidae 1095 97 88.6 (72.6-108.1) -
Secondigravidae 1146 58 50.6 (39.1-65.56) 0.6 (0.42-0.79)
Multigravidae 3300 62 18.8 (14.65-24.1) 0.2 (0.17-0.31)
By SP doses received
2 doses SP 2453 113 46.1 (38.3-55.4) -
3 doses SP 884 21 23.8 (15.5-36.4) 0.5 (0.28-0.66)
By Supplementation group
MMS 2726 110 40.3 (33.5-48.6) -
FSS 2815 107 38.0 (31.5-46.0) 0.9 (0.67-1.18)
* Women-month
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ence was observed between women infected in the sec-
ond trimester and women infected in the third trimester
(Crude IRR = 1.49, 95%CI: 0.78-2.87, p = 0.23 and
Adjusted IRR = 1.58, 95%CI: 0.83-2.98; p = 0.16).
Most women had just one infection though some of
them experienced up to four infections until delivery.
Though the LBW risk seemed to be significantly higher
in women with two or more infections as shown by the
crude IRR, the difference disappeared after adjusting for
women age, parity, body mass index, number of SP doses
received and malaria season at delivery (Table 4). Simi-
larly, the risk for maternal anaemia, though apparently
increased by two or more infection, did not vary signifi-
cantly with the number of re-infections after adjustment
by the variables mentioned above. The risk of perinatal
mortality was similar for women with ≥ 1 infection and
those with no infection (adjusted IRR = 0.87, 95% CI
0.27-2.83) (Table 4).
Discussion
The risk of delivering a LBW baby was significantly
higher in women infected during the first trimester of
pregnancy, even after adjusting for several potential con-
founding variables such as parity and number of IPTp/SP
doses received. Thought the pathogenesis and immunity
of malaria in pregnancy has been explored, the contribu-
tion of placental immuno-pathology to anaemia and
LBW is not fully understood [25]. Plasmodium falci-
parum-infected erythrocytes sequester in the placenta
through adhesion mechanisms, inducing placental
inflammatory responses, particularly monocytes infil-
trates. Inflammatory cytokines produced by T cell and
macrophages, in particular Th1 responses are associated
with maternal anaemia, spontaneous abortions and pre-
mature deliveries. These cytokines are known to help
eliminate the parasites from the placenta but their over-
production can threaten the pregnancy [25,26]. Acute
infection, particularly with high parasites densities have
been associated with preterm delivery while chronic
infection have been associated with LBW due to intrau-
terine growth retardation (IUGR) and severe anaemia
[27]. Decreased placental growth and/or decreased nutri-
ent transport have been suggested as the possible final
common pathways by which malaria leads to IUGR
[25,28]. In this study, malaria infection during the first
trimester was strongly associated with LBW. It is unclear
whether this is due to a specific consequence of the infec-
tion at this particular time, or whether it is related to the
higher risk these women have throughout their preg-
nancy. In any case, the currently recommended IPT/SP
Table 3 Crude and adjusted incidence rate ratios (IRR) of
low birth weight, maternal anaemia and perinatal
mortality by trimester of malaria infection using Poisson
regression
Crude IRR
(95%CI)
Adjusted IRR
(95%CI)
Maternal anaemia
No infection (391/816) 1.00 1.00
Infection in 1
st trimester
(15/31)
1.00 (0.69-1.46) 0.98 (0.67-1.42)
Infection in 2
nd trimester
(34/69)
1.03 (0.80-1.32) 0.99 (0.76-1.27)
Infection in 3
rd trimester
(58/118)
1.02 (0.84-1.24) 0.97 (0.79-1.20)
Low birth weight
No infection(96/816) 1.00 1.00
Infection in 1
st trimester
(13/31)
3.56 (2.26-5.61)
a 2.07 (1.30-3.27)
b
Infection in 2
nd trimester
(14/69)
1.72 (1.04-2.85)
c 1.09 (0.65-1.82)
Infection in 3
rd trimester
(16/118)
1.15 (0.70-1.88) 0.78 (0.46-1.32)
Perinatal mortality
No infection(15/816) 1.00 1.00
Infection in 1
st trimester
(0/31)
--
Infection in 2
nd trimester
(3/69)
2.36 (0.70-7.97) 1.18 (0.31-4.47)
Infection in 3
rd trimester
(1/118)
0.46 (0.06-3.46) 0.37 (0.04-2.81)
Adjusted IRR accounted for women age, parity, BMI, SP doses received and
delivery season.
ap < 0.001,
b p = 0.002,
c p = 0.034
Table 4 Crude and adjusted incident rate ratios (IRR) of
low birth weight, maternal anaemia and perinatal
mortality by number of detected malaria infection using
Poisson regression
Crude IRR (95%
CI)
Adjusted IRR(95%
CI)
Maternal anaemia
No infection (391/816) 1.00 1.00
1 infection detected
(79/169)
1.07 (0.91-1.26) 1.019 (0.85-1.21)
≥ 2 infections detected
(28/49)
1.33 (1.04-1.69)
a 1.236 (0.94-1.62)
Low birth weight
No infection (96/816) 1.00 1.00
1 infection detected
(31/169)
1.56 (1.08-2.26)
b 1.07 (0.73-1.58)
≥ 2 infections detected
(12/49)
2.08 (1.29-3.52)
c 1.08 (0.62-1.87)
Perinatal mortality
No infection (15/816) 1.00 1.00
1 infection detected
(4/169)
1.28 (0.43-3.83) 0.87 (0.27-2.83)
≥ 2 infections detected
(0/49)
--
Adjusted IRR accounted for women age, parity, BMI, SP doses received and
delivery season.
a p = 0.023,
b p = 0.19,
c p = 0.006
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SP dose should not be given before quickening, at about
20 weeks of gestation, for fear of possible toxicity for the
foetus [29]. There is little information on the use of SP
during the first trimester of pregnancy; available reports
are limited to small case series from developed countries
[15]. Therefore, the only option available for protecting
pregnant women during this vulnerable period is the use
of long-lasting insecticidal nets (LLIN) whose coverage
and use in sub-Saharan Africa, despite major efforts such
as campaigns of free mass distribution, is less than opti-
mal [30,31]. A potentially interesting additional strategy
might be the systematic screening and treatment of all
pregnant women and this option was recently investi-
gated [32,33]. However, when considering the difficulty
of identifying women at the earliest stage of their preg-
nancy [34], such an approach would hardly solve the pro-
blem of protecting during the first trimester. Therefore,
promoting LLIN through community-based promotional
campaigns targeted not only at pregnant women but also
at adolescents seems to be the only option available to
tackle this specific problem.
T h er a t eo fr e - i n f e c t i o na n dt h et i m el e n g t ht or e -
infection were suggested as possible indicators to evalu-
ate the preventive efficacy of SP [35]. In this study, the
incidence of re-infections was much higher in women
having received two as compared to three doses of SP,
indicating that the latter is probably more efficacious.
Nevertheless, the rate of re-infection was established
after treatment with quinine and does not necessarily
represent the true preventive efficacy of SP.
The study has some limitations. Information on LLIN
ownership and use was not collected and, knowing that
this has an impact on the malaria risk during pregnancy
[36], it should probably have been considered as an
important confounding factor. However, it is unlikely
that this has resulted in biased estimates as LLIN use in
the study population was probably very low at the time
of the study. In Boromo, a neighbouring district, LLIN
use was estimated at about 27% in the high transmission
season [21].
Malaria infection during pregnancy was probably under-
estimated as it was detected by peripheral blood smears.
Placental biopsies were collected during the study but
could not be analyzed due to budget constraints.
Despite the network of home visitors implemented and
the daily visits carried out for an earlier identification of
pregnant women, most of those detected during the first
trimester were at ≥ 10 weeks of gestation, a limiting fac-
tor for the assessment of infections during the first trime-
ster. For some reasons, mainly socio-cultural factors [34],
women were reluctant to declare their pregnancy earlier
and this should be further investigated.
In conclusion, malaria infections occurring in the first
trimester of pregnancy seem to have an important effect
on LBW, though the mechanisms are not yet under-
stood. Women should be encouraged to use LLIN
throughout their pregnancy so that the deleterious effect
of malaria infection during the first trimester could be
prevented.
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